Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06295588 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
A Phase 2 study of Inflammation and Fatigue, sponsored by University of Rochester.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06295588 is a Phase 2 study of Inflammation and Fatigue that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 40 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06295588, a Phase 2 study of Inflammation and Fatigue, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the feasibility of an 8-week fucoidan supplement intervention for patients with fatigue post-cancer treatment and assess changes in fatigue, frailty, and inflammation.
Conditions Studied
Interventions
- DRUG Fucoidan extracted from F. Vesiculosus
- DRUG Fucoidan extracted from U. Pinnatifida
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-07-26 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06295588
The ClinicalTrials.gov registry entry for NCT06295588 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (86% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Fucoidan extracted from F. Vesiculosus is the first listed.
NCT06295588 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06295588 about?
NCT06295588 is a clinical study titled "Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer". To determine the feasibility of an 8-week fucoidan supplement intervention for patients with fatigue post-cancer treatment and assess changes in fatigue, frailty, and inflammation.
What is the current status of trial NCT06295588?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-07-26. Estimated completion is 2027-06-01.
What conditions does trial NCT06295588 study?
This clinical trial studies the following conditions: Inflammation, Fatigue.
What interventions are being tested in trial NCT06295588?
The interventions under investigation include: Fucoidan extracted from F. Vesiculosus (DRUG), Fucoidan extracted from U. Pinnatifida (DRUG).
Who is sponsoring clinical trial NCT06295588?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06295588 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
-
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
RECRUITING · Phase 2
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Modulating Exercise Dosage to Improve Concussion Recovery
RECRUITING · Phase 2
-
Passive Stretching in Peripheral Arterial Disease Patients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.